Small Interfering RNA (siRNA) Archives

FDA approves Novartis’ first-in-class siRNA Leqvio to lower cholesterol

"Bad" LDL Cholesterol, Active Psoriatic Arthritis (PsA), Blockbusters, Clinical Trials, First-In-Class, New Indications, Novartis, R&D, Small Interfering RNA (siRNA), Therapeutics

The U.S. Food and Drug Administration approved Novartis’ Leqvio (inclisiran), the first small interfering RNA (siRNA) therapy to lower low-density lipoprotein cholesterol (also known as bad cholesterol or LDL-C) with two doses a year, after an initial dose and one at three months.

December 22, 2021/by Andrew Humphreys

RNAi-Focused Atalanta Therapeutics Launches

Alzheimer’s Disease, Biogen, Business, CNS Disorders, Collaborations, Company Launches, Deals, Financing, Genentech, Huntington’s disease, Neurodegenerative Diseases, Parkinson’s disease, RNA Interference (RNAi), RNAi therapeutics, Series A, Small Interfering RNA (siRNA)

RNAi-focused Atalanta Therapeutics launched with $110 million in combined Series A funding and collaboration deals with Genentech and Biogen to address diseases related to the central nervous system, including Huntington’s, Alzheimer’s and Parkinson’s diseases.

January 11, 2021/by Andrew Humphreys